The Experts below are selected from a list of 15705 Experts worldwide ranked by ideXlab platform
Vanderson Rocha - One of the best experts on this subject based on the ideXlab platform.
-
improving engraftment and Immune Reconstitution in umbilical cord blood transplantation
Frontiers in Immunology, 2014Co-Authors: Robert Danby, Vanderson RochaAbstract:Umbilical cord blood (UCB) is an important source of haematopoietic stem cells (HSC) for allogeneic transplantation when HLA-matched sibling and unrelated donors (MUD) are unavailable. Although the overall survival rates of UCB transplantation are comparable to the results with MUD, UCB transplants are associated with slow engraftment, delayed Immune Reconstitution, and increased opportunistic infections. While this may be a consequence of the lower cell dose in UCB grafts, it also reflects the relative immaturity of cellular immunity within cord blood. Furthermore, the limited number of cells and the non-availability of donor lymphocyte infusions (DLI) currently prevent the use of post-transplant cellular immunotherapy to boost donor-derived immunity to treat infection, mixed chimerism and disease relapse. Therefore, to further develop UCB transplantation, many strategies to enhance engraftment and Immune Reconstitution are currently under investigation. This review summarises our current understanding of engraftment and Immune recovery following UCB transplantation and why this differs from allogeneic transplants using other sources of HSC. It also provides an comprehensive overview of the promising techniques being used to improve myeloid and lymphoid recovery, including expansion, homing, and delivery of UCB HSC; combined use of UCB with third party donors; isolation and expansion of NK cells, pathogen specific T cells, and regulatory T cells; methods to protect and/or improve thymopoiesis. As many of these strategies are now in clinical trials, it is anticipated that UCB transplantation will continue to advance, further expanding our understanding of UCB biology and HSC transplantation.
-
improving engraftment and Immune Reconstitution in umbilical cord blood transplantation
Frontiers in Immunology, 2014Co-Authors: Robert Danby, Vanderson RochaAbstract:Umbilical cord blood (UCB) is an important source of hematopoietic stem cells (HSC) for allogeneic transplantation when HLA-matched sibling and unrelated donors (MUD) are unavailable. Although the overall survival results for UCB transplantation are comparable to the results with MUD, UCB transplants are associated with slow engraftment, delayed Immune Reconstitution, and increased opportunistic infections. While this may be a consequence of the lower cell dose in UCB grafts, it also reflects the relative immaturity of cord blood. Furthermore, limited cell numbers and the non-availability of donor lymphocyte infusions currently prevent the use of post-transplant cellular immunotherapy to boost donor-derived immunity to treat infections, mixed chimerism, and disease relapse. To further develop UCB transplantation, many strategies to enhance engraftment and Immune Reconstitution are currently under investigation. This review summarizes our current understanding of engraftment and Immune recovery following UCB transplantation and why this differs from allogeneic transplants using other sources of HSC. It also provides a comprehensive overview of promising techniques being used to improve myeloid and lymphoid recovery, including expansion, homing, and delivery of UCB HSC; combined use of UCB with third-party donors; isolation and expansion of natural killer cells, pathogen-specific T cells, and regulatory T cells; methods to protect and/or improve thymopoiesis. As many of these strategies are now in clinical trials, it is anticipated that UCB transplantation will continue to advance, further expanding our understanding of UCB biology and HSC transplantation.
John Koreth - One of the best experts on this subject based on the ideXlab platform.
-
Immune Reconstitution after double umbilical cord blood stem cell transplantation comparison with unrelated peripheral blood stem cell transplantation
Biology of Blood and Marrow Transplantation, 2011Co-Authors: Caron A Jacobson, Amin T Turki, Sean Mcdonough, Kristen E Stevenson, Haesook T Kim, Grace Kao, Maria I Herrera, Carol Reynolds, Edwin P Alyea, John KorethAbstract:Double umbilical cord blood (DUCB) transplantation is an accepted transplantation strategy for patients without suitable human leukocyte antigen (HLA) matched donors. However, DUCB transplantation is associated with increased morbidity and mortality because of slow recovery of immunity and a high risk of infection. To define the differences in Immune Reconstitution between DUCB transplantation and HLA matched unrelated donor (MUD) transplantation, we performed a detailed, prospective analysis of Immune Reconstitution in 42 DUCB recipients and 102 filgrastim-mobilized unrelated peripheral blood stem cell recipients. Reconstitution of CD3 T cells was significantly delayed in the DUCB cohort compared with the MUD cohort for 1 to 6 months posttransplantation (P
-
Immune Reconstitution after double umbilical cord blood stem cell transplantation comparison with unrelated peripheral blood stem cell transplantation
Biology of Blood and Marrow Transplantation, 2011Co-Authors: Caron A Jacobson, Amin T Turki, Sean Mcdonough, Kristen E Stevenson, Haesook T Kim, Grace Kao, Maria I Herrera, Carol Reynolds, Edwin P Alyea, John KorethAbstract:Double umbilical cord blood (DUCB) transplantation is an accepted transplantation strategy for patients without suitable human leukocyte antigen (HLA) matched donors. However, DUCB transplantation is associated with increased morbidity and mortality because of slow recovery of immunity and a high risk of infection. To define the differences in Immune Reconstitution between DUCB transplantation and HLA matched unrelated donor (MUD) transplantation, we performed a detailed, prospective analysis of Immune Reconstitution in 42 DUCB recipients and 102 filgrastim-mobilized unrelated peripheral blood stem cell recipients. Reconstitution of CD3 T cells was significantly delayed in the DUCB cohort compared with the MUD cohort for 1 to 6 months posttransplantation ( P P = .001). CD56CD16 natural killer (NK) cells also recovered more rapidly in DUCB recipients and remained significantly greater from 1 to 24 months after transplantation. B cell activating factor (BAFF) levels were higher in the DUCB cohort at 1 month ( P P = .002). BAFF/CD19 B cell ratios were lower in the DUCB cohort at 3 ( P = .045), 6 ( P = .02), and 12 months ( P = .002) after transplantation. DUCB recipients had more infections within the first 100 days after transplantation ( P P
Robert Danby - One of the best experts on this subject based on the ideXlab platform.
-
improving engraftment and Immune Reconstitution in umbilical cord blood transplantation
Frontiers in Immunology, 2014Co-Authors: Robert Danby, Vanderson RochaAbstract:Umbilical cord blood (UCB) is an important source of haematopoietic stem cells (HSC) for allogeneic transplantation when HLA-matched sibling and unrelated donors (MUD) are unavailable. Although the overall survival rates of UCB transplantation are comparable to the results with MUD, UCB transplants are associated with slow engraftment, delayed Immune Reconstitution, and increased opportunistic infections. While this may be a consequence of the lower cell dose in UCB grafts, it also reflects the relative immaturity of cellular immunity within cord blood. Furthermore, the limited number of cells and the non-availability of donor lymphocyte infusions (DLI) currently prevent the use of post-transplant cellular immunotherapy to boost donor-derived immunity to treat infection, mixed chimerism and disease relapse. Therefore, to further develop UCB transplantation, many strategies to enhance engraftment and Immune Reconstitution are currently under investigation. This review summarises our current understanding of engraftment and Immune recovery following UCB transplantation and why this differs from allogeneic transplants using other sources of HSC. It also provides an comprehensive overview of the promising techniques being used to improve myeloid and lymphoid recovery, including expansion, homing, and delivery of UCB HSC; combined use of UCB with third party donors; isolation and expansion of NK cells, pathogen specific T cells, and regulatory T cells; methods to protect and/or improve thymopoiesis. As many of these strategies are now in clinical trials, it is anticipated that UCB transplantation will continue to advance, further expanding our understanding of UCB biology and HSC transplantation.
-
improving engraftment and Immune Reconstitution in umbilical cord blood transplantation
Frontiers in Immunology, 2014Co-Authors: Robert Danby, Vanderson RochaAbstract:Umbilical cord blood (UCB) is an important source of hematopoietic stem cells (HSC) for allogeneic transplantation when HLA-matched sibling and unrelated donors (MUD) are unavailable. Although the overall survival results for UCB transplantation are comparable to the results with MUD, UCB transplants are associated with slow engraftment, delayed Immune Reconstitution, and increased opportunistic infections. While this may be a consequence of the lower cell dose in UCB grafts, it also reflects the relative immaturity of cord blood. Furthermore, limited cell numbers and the non-availability of donor lymphocyte infusions currently prevent the use of post-transplant cellular immunotherapy to boost donor-derived immunity to treat infections, mixed chimerism, and disease relapse. To further develop UCB transplantation, many strategies to enhance engraftment and Immune Reconstitution are currently under investigation. This review summarizes our current understanding of engraftment and Immune recovery following UCB transplantation and why this differs from allogeneic transplants using other sources of HSC. It also provides a comprehensive overview of promising techniques being used to improve myeloid and lymphoid recovery, including expansion, homing, and delivery of UCB HSC; combined use of UCB with third-party donors; isolation and expansion of natural killer cells, pathogen-specific T cells, and regulatory T cells; methods to protect and/or improve thymopoiesis. As many of these strategies are now in clinical trials, it is anticipated that UCB transplantation will continue to advance, further expanding our understanding of UCB biology and HSC transplantation.
Mark Bosch - One of the best experts on this subject based on the ideXlab platform.
-
Immune Reconstitution after anti thymocyte globulin conditioned hematopoietic cell transplantation
Cytotherapy, 2012Co-Authors: Mark Bosch, Manveer Dhadda, Mette Hoeghpetersen, Laura M Hagel, Peter Podgorny, Alejandra Ugartetorres, Joanne Luider, Iwona Auergrzesiak, Faisal Khan, Adnan MansoorAbstract:Background aims. Anti-thymocyte globulin (ATG) is being used increasingly to prevent graft-versus-host disease (GvHD); however, its impact on Immune Reconstitution is relatively unknown. We (i) studied Immune Reconstitution after ATG-conditioned hematopoietic cell transplantation (HCT), (ii) determined the factors influencing the Reconstitution, and (iii) compared it with non-ATG-conditioned HCT. Methods. Immune cell subset counts were determined at 1–24 months post-transplant in 125 HCT recipients who received ATG during conditioning. Subset counts were also determined in 46 non-ATG-conditioned patients (similarly treated). Results. (i) Reconstitution after ATG-conditioned HCT was fast for innate Immune cells, intermediate for B cells and CD8 T cells, and very slow for CD4 T cells and invariant natural killer T (iNKT) (iNKT) cells. (ii) Faster Reconstitution after ATG-conditioned HCT was associated with a higher number of cells of the same subset transferred with the graft in the case of memory B cells, ...
-
Immune Reconstitution after anti thymocyte globulin conditioned hematopoietic cell transplantation
Cytotherapy, 2012Co-Authors: Mark Bosch, Manveer Dhadda, Mette Hoeghpetersen, Laura M Hagel, Peter Podgorny, Alejandra Ugartetorres, Joanne Luider, Faisal Khan, Yiping Liu, Iwona AuergrzesiakAbstract:Abstract Background aims Anti-thymocyte globulin (ATG) is being used increasingly to prevent graft-versus-host disease (GvHD); however, its impact on Immune Reconstitution is relatively unknown. We (i) studied Immune Reconstitution after ATG-conditioned hematopoietic cell transplantation (HCT), (ii) determined the factors influencing the Reconstitution, and (iii) compared it with non-ATG-conditioned HCT. Methods Immune cell subset counts were determined at 1–24 months post-transplant in 125 HCT recipients who received ATG during conditioning. Subset counts were also determined in 46 non-ATG-conditioned patients (similarly treated). Results (i) Reconstitution after ATG-conditioned HCT was fast for innate Immune cells, intermediate for B cells and CD8 T cells, and very slow for CD4 T cells and invariant natural killer T (iNKT) (iNKT) cells. (ii) Faster Reconstitution after ATG-conditioned HCT was associated with a higher number of cells of the same subset transferred with the graft in the case of memory B cells, naive CD4 T cells, naive CD8 T cells, iNKT cells and myeloid dendritic cells; lower recipient age in the case of naive CD4 T cells and naive CD8 T cells; cytomegalovirus recipient seropositivity in the case of memory/effector T cells; an absence of GvHD in the case of naive B cells; lower ATG serum levels in the case of most T-cell subsets, including iNKT cells; and higher ATG levels in the case of NK cells and B cells. (iii) Compared with non-ATG-conditioned HCT, Reconstitution after ATG-conditioned HCT was slower for CD4 T cells, and faster for NK cells and B cells. Conclusions ATG worsens the Reconstitution of CD4 T cells but improves the Reconstitution of NK and B cells.
-
Immune Reconstitution after hematopoietic cell transplantation
Current Opinion in Hematology, 2012Co-Authors: Mark Bosch, Faisal Khan, Jan StorekAbstract:Purpose of reviewSuccessful Immune Reconstitution is important for decreasing posthematopoietic cell transplant (post-HCT) infections, relapse, and secondary malignancy, without increasing graft-versus-host disease (GVHD). Here we review how different parts of the Immune system recover, and the rela
Caron A Jacobson - One of the best experts on this subject based on the ideXlab platform.
-
Immune Reconstitution after double umbilical cord blood stem cell transplantation comparison with unrelated peripheral blood stem cell transplantation
Biology of Blood and Marrow Transplantation, 2011Co-Authors: Caron A Jacobson, Amin T Turki, Sean Mcdonough, Kristen E Stevenson, Haesook T Kim, Grace Kao, Maria I Herrera, Carol Reynolds, Edwin P Alyea, John KorethAbstract:Double umbilical cord blood (DUCB) transplantation is an accepted transplantation strategy for patients without suitable human leukocyte antigen (HLA) matched donors. However, DUCB transplantation is associated with increased morbidity and mortality because of slow recovery of immunity and a high risk of infection. To define the differences in Immune Reconstitution between DUCB transplantation and HLA matched unrelated donor (MUD) transplantation, we performed a detailed, prospective analysis of Immune Reconstitution in 42 DUCB recipients and 102 filgrastim-mobilized unrelated peripheral blood stem cell recipients. Reconstitution of CD3 T cells was significantly delayed in the DUCB cohort compared with the MUD cohort for 1 to 6 months posttransplantation (P
-
Immune Reconstitution after double umbilical cord blood stem cell transplantation comparison with unrelated peripheral blood stem cell transplantation
Biology of Blood and Marrow Transplantation, 2011Co-Authors: Caron A Jacobson, Amin T Turki, Sean Mcdonough, Kristen E Stevenson, Haesook T Kim, Grace Kao, Maria I Herrera, Carol Reynolds, Edwin P Alyea, John KorethAbstract:Double umbilical cord blood (DUCB) transplantation is an accepted transplantation strategy for patients without suitable human leukocyte antigen (HLA) matched donors. However, DUCB transplantation is associated with increased morbidity and mortality because of slow recovery of immunity and a high risk of infection. To define the differences in Immune Reconstitution between DUCB transplantation and HLA matched unrelated donor (MUD) transplantation, we performed a detailed, prospective analysis of Immune Reconstitution in 42 DUCB recipients and 102 filgrastim-mobilized unrelated peripheral blood stem cell recipients. Reconstitution of CD3 T cells was significantly delayed in the DUCB cohort compared with the MUD cohort for 1 to 6 months posttransplantation ( P P = .001). CD56CD16 natural killer (NK) cells also recovered more rapidly in DUCB recipients and remained significantly greater from 1 to 24 months after transplantation. B cell activating factor (BAFF) levels were higher in the DUCB cohort at 1 month ( P P = .002). BAFF/CD19 B cell ratios were lower in the DUCB cohort at 3 ( P = .045), 6 ( P = .02), and 12 months ( P = .002) after transplantation. DUCB recipients had more infections within the first 100 days after transplantation ( P P
